Episode Details
Back to EpisodesHER2+ Lung Cancer Breakthroughs: New Targeted Therapies Explained
Episode 595
Published 7 months, 3 weeks ago
Description
Drs. Herzberg and Yu explore emerging clinical data from the 2025 meetings of the European Society For Medical Oncology (ESMO) and World Conference on Lung Cancer (WCLC), highlighting recent advancements in HER2-targeted therapies for NSCLC. Their discussion focuses on new drugs (eg, zongertinib and trastuzumab deruxtecan), their efficacy and safety profiles, and the potential for treating HER2 mutations and overexpression.